Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
OPEN Circulation | 25 Nov 2016
CM Gibson, S Korjian, P Tricoci, Y Daaboul, M Yee, P Jain, JH Alexander, PG Steg, AM Lincoff, JJ Kastelein, R Mehran, DM D'Andrea, LI Deckelbaum, B Merkely, M Zarebinski, T Oude Ophuis and RA Harrington
-Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction.
* Data courtesy of Altmetric.com